154 related articles for article (PubMed ID: 31332268)
1. Risk of disease progression in low-risk MDS is linked to distinct epigenetic subtypes.
Qin T; Sotzen J; Rampal RK; Rapaport FT; Levine RL; Klimek V; Nimer SD; Figueroa ME
Leukemia; 2019 Nov; 33(11):2753-2757. PubMed ID: 31332268
[No Abstract] [Full Text] [Related]
2. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.
Schuler E; Frank F; Hildebrandt B; Betz B; Strupp C; Rudelius M; Aul C; Schroeder T; Gattermann N; Haas R; Germing U
Leuk Res; 2018 Feb; 65():1-4. PubMed ID: 29216536
[TBL] [Abstract][Full Text] [Related]
3. Epigenetics in myeloid malignancies.
Deneberg S
Methods Mol Biol; 2012; 863():119-37. PubMed ID: 22359290
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
[TBL] [Abstract][Full Text] [Related]
6. Interpreting new molecular genetics in myelodysplastic syndromes.
Abdel-Wahab O; Figueroa ME
Hematology Am Soc Hematol Educ Program; 2012; 2012():56-64. PubMed ID: 23233561
[TBL] [Abstract][Full Text] [Related]
7.
Abuhadra N; Mukherjee S; Al-Issa K; Adema V; Hirsch CM; Advani A; Przychodzen B; Makhoul A; Awada H; Maciejewski JP; Sekeres MA; Nazha A
Leuk Lymphoma; 2019 Jun; 60(6):1587-1590. PubMed ID: 30618304
[No Abstract] [Full Text] [Related]
8. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
[TBL] [Abstract][Full Text] [Related]
9. Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.
Abáigar M; Robledo C; Benito R; Ramos F; Díez-Campelo M; Hermosín L; Sánchez-Del-Real J; Alonso JM; Cuello R; Megido M; Rodríguez JN; Martín-Núñez G; Aguilar C; Vargas M; Martín AA; García JL; Kohlmann A; Del Cañizo MC; Hernández-Rivas JM
PLoS One; 2016; 11(10):e0164370. PubMed ID: 27741277
[TBL] [Abstract][Full Text] [Related]
10. Unraveling the molecular pathophysiology of myelodysplastic syndromes.
Bejar R; Levine R; Ebert BL
J Clin Oncol; 2011 Feb; 29(5):504-15. PubMed ID: 21220588
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Markers of Myelodysplastic Syndromes.
Veryaskina YA; Titov SE; Kovynev IB; Pospelova TI; Zhimulev IF
Medicina (Kaunas); 2020 Jul; 56(8):. PubMed ID: 32727068
[TBL] [Abstract][Full Text] [Related]
13. Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms.
Bartels S; Schipper E; Hasemeier B; Kreipe H; Lehmann U
Oncotarget; 2016 May; 7(21):30084-93. PubMed ID: 27029036
[TBL] [Abstract][Full Text] [Related]
14. Age-related epigenetic drift in the pathogenesis of MDS and AML.
Maegawa S; Gough SM; Watanabe-Okochi N; Lu Y; Zhang N; Castoro RJ; Estecio MR; Jelinek J; Liang S; Kitamura T; Aplan PD; Issa JP
Genome Res; 2014 Apr; 24(4):580-91. PubMed ID: 24414704
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes.
del Rey M; O'Hagan K; Dellett M; Aibar S; Colyer HA; Alonso ME; Díez-Campelo M; Armstrong RN; Sharpe DJ; Gutiérrez NC; García JL; De Las Rivas J; Mills KI; Hernández-Rivas JM
Leukemia; 2013 Mar; 27(3):610-8. PubMed ID: 22936014
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response.
Siamoglou S; Boers R; Koromina M; Boers J; Tsironi A; Chatzilygeroudi T; Lazaris V; Verigou E; Kourakli A; van IJcken WFJ; Gribnau J; Symeonidis A; Patrinos GP
Hum Genomics; 2023 Apr; 17(1):37. PubMed ID: 37098643
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of RUNX3 Represses RUNX1 to Drive Transformation of Myelodysplastic Syndrome.
Yokomizo-Nakano T; Kubota S; Bai J; Hamashima A; Morii M; Sun Y; Katagiri S; Iimori M; Kanai A; Tanaka D; Oshima M; Harada Y; Ohyashiki K; Iwama A; Harada H; Osato M; Sashida G
Cancer Res; 2020 Jun; 80(12):2523-2536. PubMed ID: 32341038
[TBL] [Abstract][Full Text] [Related]
18. [Mutations in TET2 in myeloid cancers].
Bernard OA; Delhommeau F; Fontenay M; Vainchenker W
Med Sci (Paris); 2009 Oct; 25(10):785-8. PubMed ID: 19849974
[No Abstract] [Full Text] [Related]
19. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.
Jiang Y; Dunbar A; Gondek LP; Mohan S; Rataul M; O'Keefe C; Sekeres M; Saunthararajah Y; Maciejewski JP
Blood; 2009 Feb; 113(6):1315-25. PubMed ID: 18832655
[TBL] [Abstract][Full Text] [Related]
20. Mutations in chronic myelomonocytic leukemia and their prognostic relevance.
Jian J; Qiao Y; Li Y; Guo Y; Ma H; Liu B
Clin Transl Oncol; 2021 Sep; 23(9):1731-1742. PubMed ID: 33861431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
